Pancreastatin, a
neuropeptide derived from
chromogranin A, has a glycogenolytic and counterregulatory effect to
insulin in the rat liver. This effect is mediated by
calcium and
protein kinase C activity. Our aim was to study the possible cross-talk between
pancreastatin and the
insulin signalling system, by using the well-studied
insulin sensitive rat
hepatoma HTC cells. First, we checked the counterregulatory effect of
pancreastatin on
insulin action.
Pancreastatin dose-dependently inhibited
insulin stimulated
glycogen synthesis. This effect was not due to competition for
insulin receptors. Moreover, when
protein kinase C activation was blocked with
staurosporine, this effect of
pancreastatin was not observed. Next, we found a dose-dependent inhibition of
insulin receptor autophosphorylation by
pancreastatin. In addition, phosphorylation of the major substrates of
insulin receptor in HTC, i. e.
insulin-receptor substrate (IRS)-1/IRS-2 and p62 was also blunted and so was its association with p85 regulatory subunit of phosphatidylinositol-3-kinase. Moreover, the
insulin activation of
S6 kinase was also blocked by
pancreastatin. Again, all these inhibitory effects of
pancreastatin were prevented by
staurosporine. Furthermore,
pancreastatin produced Ser/Thr phosphorylation of
insulin receptor by a
staurosporine-sensitive mechanism. Finally, we checked the
pancreastatin activation of
protein kinase C in HTC cells and found that a "classical"
isoform of this
protein is translocated to the plasma membrane. These findings suggest that
pancreastatin could exert its anti-
insulin effect in the hepatocyte by interrupting the stimulation of early
insulin receptor signalling as a result of phosphorylation. This interaction might have a role in the mechanisms of
insulin resistance.